Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency (Q46563222)

23 December 2017

title

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency (English)

1 reference

23 December 2017

0 references

0 references

Juliana Chung-ngor Chan

1

1 reference

23 December 2017

author name string

R Scott

2

1 reference

23 December 2017

J C Arjona Ferreira

3

1 reference

23 December 2017

D Sheng

4

1 reference

23 December 2017

E Gonzalez

5

1 reference

23 December 2017

M J Davies

6

1 reference

23 December 2017

P P Stein

7

1 reference

23 December 2017

K D Kaufman

8

1 reference

23 December 2017

J M Amatruda

9

1 reference

23 December 2017

D Williams-Herman

10

1 reference

23 December 2017

publication date

1 June 2008

1 reference

23 December 2017

Diabetes, Obesity and Metabolism

published in

1 reference

23 December 2017

volume

10

1 reference

23 December 2017

page(s)

545-555

1 reference

23 December 2017

issue

7

1 reference

23 December 2017

Screening for kidney disease in adults with diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Diabetic nephropathy: diagnosis, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Antihypertensive therapy in the presence of proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Oral antihyperglycemic agents and renal disease: new agents, new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Management of glycemia in patients with diabetes mellitus and CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Impact of diabetic nephropathy on pharmacodynamic and Pharmacokinetic properties of insulin in type 1 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2008.00914.X

10.1111/J.1463-1326.2008.00914.X

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

PubMed ID

18518892

1 reference

23 December 2017